125 related articles for article (PubMed ID: 2318450)
1. Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass.
Cole LA; Nam JH; Chambers JT; Schwartz PE
Gynecol Oncol; 1990 Mar; 36(3):391-4. PubMed ID: 2318450
[TBL] [Abstract][Full Text] [Related]
2. Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.
Cole LA; Nam JH
Yale J Biol Med; 1989; 62(4):367-78. PubMed ID: 2596125
[TBL] [Abstract][Full Text] [Related]
3. Urinary gonadotropin fragment, a new tumor marker. I. Assay development and cancer specificity.
Nam JH; Cole LA; Chambers JT; Schwartz PE
Gynecol Oncol; 1990 Mar; 36(3):383-90. PubMed ID: 2318449
[TBL] [Abstract][Full Text] [Related]
4. The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses.
Carter PG; Iles RK; Neven P; Davies AP; Shepherd JH; Chard T
Gynecol Oncol; 1993 Dec; 51(3):368-71. PubMed ID: 8112647
[TBL] [Abstract][Full Text] [Related]
5. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. I. Sensitivity and specificity, comparison with other markers.
Cole LA; Schwartz PE; Wang YX
Gynecol Oncol; 1988 Sep; 31(1):82-90. PubMed ID: 3044936
[TBL] [Abstract][Full Text] [Related]
6. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
7. Urinary gonadotropin fragment, a new tumor marker. III. Use in cervical and vulvar cancers.
Nam JH; Chang KC; Chambers JT; Schwartz PE; Cole LA
Gynecol Oncol; 1990 Jul; 38(1):66-70. PubMed ID: 2354828
[TBL] [Abstract][Full Text] [Related]
8. Urinary gonadotropin fragment measurements in patients with lung and esophageal disease.
D'Agostino RS; Cole LA; Ponn RB; Stern H; Schwartz PE
J Surg Oncol; 1992 Mar; 49(3):147-50. PubMed ID: 1548888
[TBL] [Abstract][Full Text] [Related]
9. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. II. Initial serial studies.
Wang YX; Schwartz PE; Chambers JT; Cole LA
Gynecol Oncol; 1988 Sep; 31(1):91-102. PubMed ID: 3410359
[TBL] [Abstract][Full Text] [Related]
10. Urinary gonadotropin fragment, a new tumor marker. IV. Use in endometrial cancers and uterine mixed mullerian tumors.
Nam JH; Chambers JT; Schwartz PE; Cole LA
Gynecol Oncol; 1990 Dec; 39(3):352-7. PubMed ID: 2175287
[TBL] [Abstract][Full Text] [Related]
11. Urinary chorionic gonadotropin subunits and beta-core in nonpregnant women. A study of benign and malignant gynecologic disorders.
Neven P; Iles RK; Lee CL; Hudson CN; Shepherd JH; Chard T
Cancer; 1993 Jun; 71(12):4124-30. PubMed ID: 7685240
[TBL] [Abstract][Full Text] [Related]
12. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
13. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
14. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
15. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
Chen DX; Schwartz PE; Li XG; Yang Z
Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
[TBL] [Abstract][Full Text] [Related]
17. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology.
Schwartz PE; Cracchiolo BM; Cole LA
Anticancer Res; 1996; 16(4B):2135-9. PubMed ID: 8694533
[TBL] [Abstract][Full Text] [Related]
18. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
Walker R; Crebbin V; Stern J; Scudder S; Schwartz P
Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804
[TBL] [Abstract][Full Text] [Related]
19. Improved methods for detecting beta-core in normal and cancer patient urines.
Tanaka A; Cole LA
Clin Chem; 1994 Dec; 40(12):2317-8. PubMed ID: 7988019
[No Abstract] [Full Text] [Related]
20. CA 125 in the diagnosis of pelvic masses.
Mogensen O; Mogensen B; Jakobsen A
Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1187-90. PubMed ID: 2767108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]